New
Recruits

Helene Langevin, M.D.

Director, National Center for Complementary and Integrative Health

Sworn in on November 26, 2018

Bruce Tromberg, Ph.D.

Incoming Director

National Institute of Biomedical Imaging and Bioengineering

UNITED STATES
E PLURIBUS UNUM
CONGRESS

Representative Ro Khanna

July 30, 2018



Senator Tom Udall

July 30, 2018

Senate HELP Committee Hearing

August 23, 2018

Rep. Andy Harris

GOP Doctors Caucus, September 5, 2018

AWARDS

2018 Albany Medical Center Prize in Medicine

Steven A. Rosenberg, Carl June, James Allison

September 26, 2018

NIH-Funded Nobel Prize Winners

Chemistry

Frances H. Arnold

George P. Smith

Medicine or Physiology

James Allison

Sammies 2018 Federal Employee of the Year
Daniel Kastner
October 2, 2018

Adriaan (Ad) Bax

Robert A Welch Award in Chemistry

October 2018



SPECIAL

EVENTS

Backstage with The Edge and Patients from the Children's Inn

June 18, 2018

Music and the Mind 2nd Annual Concert/Workshop

September 7, 2018

Grand Opening: Clinical Center's Hospice Suites

July 10, 2018

NIH Distinguished Scholars Program

October 1, 2018

SCIENCE

ADVANCES

Media Advisory Tuesday, December 4, 2018

NIH researcher presents encouraging results for gene therapy for severe sickle cell disease

Tuesday, December 4, 2018

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

Tuesday, November 27, 2018

Clinical trial of investigational Ebola treatments begins in the Democratic Republic of the Congo

Friday, November 2, 2018

NIH greatly expands investment in BRAIN Initiative

NIH announces new round of awards for cutting-edge brain research.

Sunday, September 16, 2018

Daily low-dose aspirin found to have no effect on healthy life span in older people

Large NIH-funded study examined outcomes in United States and Australia

Tuesday, June 19, 2018

Methadone and buprenorphine reduce risk of death after opioid overdose

NIH research confirms effective treatments for opioid use disorder are underutilized.

Tuesday, September 25, 2018

NIH-funded genome centers to accelerate precision medicine discoveries

Part of the All of Us Research Program, centers will sequence 1 million genomes.

Cure Sickle Cell Initiative



Public-Private Partnership
Leverage networks to accelerate cures

Patient Outcomes
Perform clinical and economic impact analysis as a resource

Patient Engagement
Establish community of patients, caregivers, advocates

Clinical Strategies
Support promising research; develop meaningful endpoints for GT trials

Data Management
Develop robust systems for patients and researchers

Biomanufacturing
Reagent manufacturing, biospecimen, regulatory resources for researchers

December 10, 2018

NIH needs your innovative research ideas through our newly announced NIH HEAL Initiative funding opportunities

NIH leadership from across the agency has been working diligently over the past several months to identify areas of greatest opportunity for research to address the national opioid crisis. The result is more than 30 new funding opportunity announcements (FOAs) to solicit the best and brightest research ideas through the NIH HEAL (Helping to End Addiction Long-term[SM]) Initiative.

Through these and other investments, NIH plans to award more than $850 million in support of HEAL Initiative research in fiscal year (FY) 2019 (from funds appropriated in FY 2018 and FY 2019). This adds to a substantial investment made by NIH Institutes and Centers (ICs) in the areas of pain, addiction, complementary medicine, and much more.

Global
Health Issues

International Cohorts Summit

March 26–27, 2018 ♦ Durham, NC

KEEP
CALM
AND
COMPLY WITH
GDPR

BMGF-NIH Meeting with Bill Gates

December 11, 2018

In Memoriam

Remembering NCI's Alan Rabson

October 30, 2018

Remembering President George H. W. Bush

June 12, 1924 – November 30, 2018

Opening of the NIH Children's Inn
June 21, 1990

Bernadine Healy's Swearing-In
June 24, 1991

The Academy of Sciences of Hong Kong 香港科學院 | NATIONAL ACADEMY OF SCIENCES | NATIONAL ACADEMY OF MEDICINE Leadership · Innovation · Impact | for a healthier future | THE ROYAL SOCIETY

Overview of genomic data



one 6kb deletion at on-target site

“Lest there be any doubt, and as we have stated previously, NIH does not support the use of gene-editing technologies in human embryos.”

November 28, 2018

Statement on Claim of First Gene-Edited Babies by Chinese Researcher



CRISPR-Cas9 is a customizable tool that lets scientists cut and insert small pieces of DNA at precise areas along a DNA strand. This lets scientists study our genes in a specific, targeted way. *Image Credit: Ernesto del Aguila III, NHGRI.*

NIH is deeply concerned about the work just presented at the Second International Summit on Human Genome Editing in Hong Kong by Dr. He Jiankui, who described his effort using CRISPR-Cas9 on human embryos to disable the CCR5 gene. He claims that the two embryos were subsequently implanted, and infant twins have been born. This work represents a deeply disturbing willingness by Dr. He and his team to flout international ethical norms. The project was largely carried out in secret, the medical necessity for inactivation of CCR5 in these infants is utterly unconvincing, the informed consent process appears highly questionable, and the possibility of damaging off-target effects has not been satisfactorily explored. It is profoundly unfortunate that the first apparent application of this powerful technique to the human germline has been carried out so irresponsibly. The need for development of binding international consensus on setting limits for this kind of research, now being debated in Hong Kong, has never been more apparent. Without such limits, the world will face the serious risk of a deluge of similarly ill-considered and unethical projects. Should such epic scientific misadventures proceed, a technology with enormous promise for prevention and treatment of disease will be overshadowed by justifiable public outrage, fear, and disgust.

NIH's Somatic Cell Genome Editing Program

- Launched December 10-11, 2018
- New program to speed development of safe, effective editing tools for *in vivo* applications in human patients
- Awarding $190M over six years to:
  - Develop new technologies for improving *in vivo* delivery of genome editing tools
  - Improve safety and efficacy testing
  - Make tools, data widely available






NIH… *Turning Discovery Into Health*

directorsblog.nih.gov @NIHDirector